Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

MT-1186

Aliases
Edaravone, Oral edaravone

10 clinical trials

3 indications

Indication
Adult Health
Indication
Amyotrophic Lateral Sclerosis
Indication
Amyotrophic Lateral Sclerosis (ALS)
Clinical trial
Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects
Status: Completed, Estimated PCD: 2019-04-21
Clinical trial
A Phase I, Randomized, Open-Label, Crossover-Design, Single-Dose Study to Investigate the Safety, Tolerability and Comparative Bioavailability of Oral Edaravone Administered Orally and Via a Nasogastric Tube (NGT) in Healthy Adult Subjects
Status: Completed, Estimated PCD: 2021-04-01
Clinical trial
Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Completed, Estimated PCD: 2019-09-04
Clinical trial
Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With Gastrostomy
Status: Completed, Estimated PCD: 2020-04-16
Clinical trial
Safety Study of Oral Edaravone Administered in Subjects With ALS
Status: Completed, Estimated PCD: 2021-10-07
Clinical trial
A Phase 3, Multi-center, Open-label, Safety Extension Study of Oral Edaravone Administered Over 96 Weeks in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Status: Completed, Estimated PCD: 2023-08-08
Clinical trial
Multicenter, Open-label Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Status: Completed, Estimated PCD: 2023-06-27
Clinical trial
A Phase 3b, Multicenter, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Oral Edaravone Administered for a Period of 48 Weeks in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Status: Terminated, Estimated PCD: 2023-09-29
Clinical trial
Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Subjects (Food Effect Study)
Status: Completed, Estimated PCD: 2019-07-24
Clinical trial
A Phase 3b, Multicenter, Randomized, Double-blind Extension Study to Evaluate the Continued Efficacy and Safety of Oral Edaravone Administered for an Additional Period of up to 48 Weeks Following Study MT-1186-A02 in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Status: Terminated, Estimated PCD: 2023-09-29